Ibandronic acid concentracted solution for infusions 1 mg/ml. 6 ml. (6 mg.)

Description

Ibandronic 1 mg/ml Pharmachologic effect

Inhibitor of bone resorption and osteoclast activity, highly active nitrogen-containing bisphosphonate.

Ibandronic acid is a highly active nitrogen-containing bisphosphonate, an inhibitor of bone resorption and osteoclast activity. Ibandronic acid prevents bone destruction caused by blockage of gonadal function, retinoids, tumors and tumor extracts in vivo.

Ibandronic acid does not interfere with bone mineralization when administered in therapeutic doses for the treatment of osteoporosis and does not affect the process of replenishing the osteoclast pool. The selective action of ibandronic acid on bone tissue is due to its high affinity for hydroxyapatite, which is the mineral matrix of the bone.

Ibandronic acid dose-dependently inhibits bone resorption and has no direct effect on bone formation. In menopausal women, it reduces the increased rate of bone turnover to the level of reproductive age, which leads to an overall progressive increase in bone mass, a decrease in the rates of bone collagen degradation (concentration of deoxypyridinoline and cross-linked C- and N-telopeptides of type I collagen) in urine and serum , the frequency of fractures and an increase in bone mineral density (BMD).

The high activity and wide therapeutic range provide the possibility of a flexible dosing regimen and intermittent prescription of the drug with a long period without treatment at relatively low doses.

Bone Mineral Density (BMD)

Ibandronic 1 mg/ml Indications:

treatment of postmenopausal osteoporosis in women at increased risk of fractures. The drug reduces the risk of vertebral fractures. The effect on the risk of femoral neck fractures has not been established.

Ibandronic 1 mg/ml Contraindications:
hypocalcemia (before starting the use of Bonviva, as with the appointment of all bisphosphonates used to treat osteoporosis, hypocalcemia should be eliminated);
severe renal impairment
pregnancy;
lactation period;
childhood (safety and effectiveness in persons under 18 years of age has not been established);
hypersensitivity to ibandronic acid and other components of the drug.
Special instructions: Before starting the use of Bonviva, hypocalcemia and other disorders of bone metabolism and electrolyte balance should be corrected. Patients should consume adequate amounts of calcium and vitamin D. If the patient does not receive enough calcium and vitamin D from food, then they should be additionally taken in the form of dietary supplements.

Serum creatinine should be determined before each injection.

Patients with concomitant diseases receiving nephrotoxic therapy who may have deterioration of renal function should be closely monitored.

With the use of bisphosphonates in patients with cancer, osteonecrosis of the jaw was observed, most often associated with tooth extraction and / or local infection (in particular, osteomyelitis). Osteonecrosis of the jaw developed mainly against the background of intravenous use of bisphosphonates, which was often accompanied by chemotherapy and the use of corticosteroids.